

Mary Lou Affronti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9098381/publications.pdf>

Version: 2024-02-01

29
papers

812
citations

623188

14
h-index

552369

26
g-index

29
all docs

29
docs citations

29
times ranked

850
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase II Trial of Temozolomide in Patients With Progressive Low-Grade Glioma. <i>Journal of Clinical Oncology</i> , 2003, 21, 646-651.	0.8	246
2	Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy. <i>Cancer</i> , 2009, 115, 3501-3511.	2.0	123
3	Evaluation of GM-CSF mouthwash for prevention of chemotherapy-induced mucositis: a randomized, double-blind, dose-ranging study. <i>Cytokine</i> , 1995, 7, 471-477.	1.4	60
4	The duke afm program intensive induction chemotherapy for metastatic breast cancer. <i>Cancer</i> , 1990, 66, 431-436.	2.0	55
5	Chemotherapy-induced nausea and vomiting (CINV) and adherence to antiemetic guidelines: results of a survey of oncology nurses. <i>Supportive Care in Cancer</i> , 2018, 26, 557-564.	1.0	49
6	Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma. <i>Neuro-Oncology</i> , 2004, 6, 134-144.	0.6	42
7	Consolidation with High-Dose Combination Alkylating Agents with Bone Marrow Transplantation Significantly Improves Disease-Free Survival in Hormone-Insensitive Metastatic Breast Cancer in Complete Remission Compared with Intensive Standard-Dose Chemotherapy Alone. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 195-203.	2.0	30
8	Adherence to antiemetic guidelines in patients with malignant glioma: a quality improvement project to translate evidence into practice. <i>Supportive Care in Cancer</i> , 2014, 22, 1897-1905.	1.0	28
9	Phase II Study to Evaluate the Efficacy and Safety of Rilotumumab and Bevacizumab in Subjects with Recurrent Malignant Glioma. <i>Oncologist</i> , 2018, 23, 889-e98.	1.9	26
10	A phase I/II study of high-dose cyclophosphamide, cisplatin, and thioTEPA followed by autologous bone marrow and granulocyte colony-stimulating factor-primed peripheral-blood progenitor cells in patients with advanced malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 1996, 37, 561-568.	1.1	25
11	Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma. <i>Neuro-Oncology</i> , 2004, 6, 145-153.	0.6	24
12	High-dose carboplatin, cyclophosphamide, and BCNU with autologous bone marrow support: excessive hepatic toxicity. <i>Cancer Chemotherapy and Pharmacology</i> , 1990, 26, 155-156.	1.1	19
13	A cross sectional analysis from a single institution's experience of psychosocial distress and health-related quality of life in the primary brain tumor population. <i>Journal of Neuro-Oncology</i> , 2017, 134, 363-369.	1.4	18
14	Bone Metastases from Breast Cancer. <i>Journal of Computer Assisted Tomography</i> , 1992, 16, 608-614.	0.5	15
15	Palonosetron in the management of chemotherapy-induced nausea and vomiting in patients receiving multiple-day chemotherapy. <i>Cancer Management and Research</i> , 2014, 6, 329.	0.9	9
16	Phase II study to evaluate the safety and efficacy of intravenous palonosetron (PAL) in primary malignant glioma (MG) patients receiving standard radiotherapy (RT) and concomitant temozolomide (TMZ). <i>Supportive Care in Cancer</i> , 2016, 24, 4365-4375.	1.0	9
17	Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide. <i>Supportive Care in Cancer</i> , 2020, 28, 2229-2238.	1.0	9
18	Pilot Study to Describe the Trajectory of Symptoms and Adaptive Strategies of Adults Living with Low-grade Glioma. <i>Seminars in Oncology Nursing</i> , 2018, 34, 472-485.	0.7	7

#	ARTICLE	IF	CITATIONS
19	A Phase II single-arm trial of palonosetron for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in malignant glioma patients receiving multidose irinotecan in combination with bevacizumab. <i>Therapeutics and Clinical Risk Management</i> , 2017, Volume 13, 33-40.	0.9	6
20	Complementary and integrative health interventions and their association with health-related quality of life in the primary brain tumor population. <i>Complementary Therapies in Clinical Practice</i> , 2019, 36, 43-48.	0.7	5
21	Phase II study to evaluate the efficacy and safety of rilotumumab and bevacizumab (BEV) in subjects with recurrent malignant glioma (MG).. <i>Journal of Clinical Oncology</i> , 2012, 30, 2074-2074.	0.8	2
22	Response to the letter to the Editor concerning manuscript entitled, "Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide". <i>Supportive Care in Cancer</i> , 2020, 28, 5591-5592.	1.0	1
23	Results of a survey of oncology nurses assessing practice patterns and adherence to antiemetic guidelines.. <i>Journal of Clinical Oncology</i> , 2016, 34, e21647-e21647.	0.8	1
24	Long-term survivorship in adult primary glioblastoma: Clinical and neurological outcomes of a large, single-center study.. <i>Journal of Clinical Oncology</i> , 2014, 32, 9519-9519.	0.8	1
25	Psychosocial distress and its effects on the health-related quality of life of primary brain tumor patients.. <i>Journal of Clinical Oncology</i> , 2015, 33, 9553-9553.	0.8	1
26	Utilizing a Palliative Care Screening Tool in Patients With Glioblastoma. <i>Journal of the Advanced Practitioner in Oncology</i> , 2020, 11, 684-692.	0.2	1
27	Introduction. <i>Seminars in Oncology Nursing</i> , 2018, 34, 417-419.	0.7	0
28	Secondary cancers in long-term survivors of primary glioblastoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, e20616-e20616.	0.8	0
29	Development of a Professional Practice Model for Neuro-oncology Advanced Practitioners at an Academic Medical Center: A Quality Improvement Project. <i>Journal of the Advanced Practitioner in Oncology</i> , 2018, 9, 475-486.	0.2	0